| Literature DB >> 35338200 |
Gregory S McElroy1, Ram P Chakrabarty1, Karis B D'Alessandro1, Yuan-Shih Hu1, Karthik Vasan1, Jerica Tan1, Joshua S Stoolman1, Samuel E Weinberg2, Elizabeth M Steinert1, Paul A Reyfman1, Benjamin D Singer1, Warren C Ladiges3, Lin Gao4,5,6, José Lopéz-Barneo4,5,6, Karen Ridge1, G R Scott Budinger1, Navdeep S Chandel7,8.
Abstract
Aging in mammals leads to reduction in genes encoding the 45-subunit mitochondrial electron transport chain complex I. It has been hypothesized that normal aging and age-related diseases such as Parkinson's disease are in part due to modest decrease in expression of mitochondrial complex I subunits. By contrast, diminishing expression of mitochondrial complex I genes in lower organisms increases lifespan. Furthermore, metformin, a putative complex I inhibitor, increases healthspan in mice and humans. In the present study, we investigated whether loss of one allele of Ndufs2, the catalytic subunit of mitochondrial complex I, impacts healthspan and lifespan in mice. Our results indicate that Ndufs2 hemizygous mice (Ndufs2+/-) show no overt impairment in aging-related motor function, learning, tissue histology, organismal metabolism, or sensitivity to metformin in a C57BL6/J background. Despite a significant reduction of Ndufs2 mRNA, the mice do not demonstrate a significant decrease in complex I function. However, there are detectable transcriptomic changes in individual cell types and tissues due to loss of one allele of Ndufs2. Our data indicate that a 50% decline in mRNA of the core mitochondrial complex I subunit Ndufs2 is neither beneficial nor detrimental to healthspan.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35338200 PMCID: PMC8956724 DOI: 10.1038/s41598-022-09074-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 2Longitudinal behavioral analysis of Ndufs2+/- and Ndufs2+/+ mice. (a) Novel object recognition test total exploration time. Male and female data combined. n = 7–25 per group, multiple t-tests not significant. (b) Novel object recognition test discrimination index. Male and female data combined. n = 7–25 per group, multiple t-tests not significant. (c) Female forced maximal exercise on accelerating treadmill challenge total time on treadmill. n = 4–8. Multiple t-tests not significant. (d) Male forced maximal exercise on accelerating treadmill challenge total time on treadmill. n = 2–6. Multiple t-tests not significant. (e) Female day 1 accelerating rotarod challenge latency to fall. n = 4–13. Multiple t-tests not significant. (f) Male day 1 accelerating rotarod challenge latency to fall. n = 5–18. Multiple t-tests not significant. (g) Female day 4 accelerating rotarod challenge latency to fall. n = 4–13. Multiple t-tests not significant. (h) Male day 4 accelerating rotarod challenge latency to fall. n = 5–18. Multiple t-tests not significant. (i) Female open field test total distance. n = 4–13. Multiple t-tests not significant. (j) Male open field test total distance. n = 5–18. Multiple t-tests not significant. (k) Female grip strength. n = 4–13. Multiple t-tests not significant. (l) Male grip strength. n = 5–18. Multiple t-tests not significant. (a–l) Multiple t-tests refers to adjusted t-tests with a two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 1% Ndufs2+/+ vs Ndufs2+/− independently for each time point. n.s. not significant by genotype.
Figure 1Ndufs2 hemizygosity decreases mRNA but does not significant impair complex I function or lifespan. (a) Ndufs2 mRNA quantification in cells and tissue. Two-way ANOVA column factor p < 0.0001, n = 2–4), Sidak’s multiple comparisons test *p < 0.05. (b) Relative complex I enzymatic activity in whole tissue. 2-way ANOVA column factor p = 0.0994 n = 5 Sidak’s multiple comparisons test not significant. (c) Survival of female Ndufs2 +/+ and Ndufs2 +/− mice n = 20–22. Log-rank (Mantel-Cox) test p = 0.0791. (d) Survival of male Ndufs2 +/+ and Ndufs2 +/- mice n = 28–29. Log-rank (Mantel-Cox) test p = 0.9842 (e) Average body weight by month of female Ndufs2 +/+ and Ndufs2 +/− mice. Multiple t-tests adjusted *p < 0.01: Female Ndufs2 +/− vs Female Ndufs2 +/+ months 6–12 and 16. N = 31–34. (f) Average body weight by month of male Ndufs2 +/+ and Ndufs2 +/− mice. n = 22. n.s. not significant.
Figure 3Ndufs2 hemizygosity alters gene expression in immune cell populations. (a) Serum IL-6 measurement in 24 month-old mice. n = 4, unpaired t-test p = 0.8919. (b) Serum TNFa measurement in 24 month-old mice. n = 4, unpaired t-test p = 0.9616. (c) Leukocyte percentage of circulating neutrophils in 27-month-old mice. n = 4, unpaired t-test p = 0.8313. (d) Leukocyte percentage of circulating monocytes in 27-month-old mice. n = 4, unpaired t-test p = 0.6048. (e) Lymphocytic choriomeningitis virus (LCMV) infection response at 20 months of age. Percentage of GP33 responsive CD8 T cells at day 0 and day 7. n = 4, unpaired t-test p = 0.9204. (f) Regulatory T cell GSEA. Demethylation gene set is the top gene ontology biological process gene set enriched in Ndufs2 +/- compared to Ndufs2 +/+ at 20 months of age. (g, h) Regulatory T cells differential gene expression analysis in 20-month-old mice. (g) Volcano plot individual gene FDR cutoff 0.05, n = 4 (h) GSEA significant MSigDB hallmark gene sets with FDR cutoff of 0.25, n = 4. (i, j) Alveolar macrophage differential gene expression analysis. (i) Volcano plot individual gene FDR cutoff 0.05, n = 4. (j) GSEA significant MSigDB hallmark gene sets with FDR cutoff of 0.25, n = 4. (k, l) CD4 cell differential gene expression analysis in 20-month-old mice. (k) Volcano plot individual gene FDR cutoff 0.05, n = 4 (l) Gene Set Enrichment Analysis (GSEA) Molecular Signatures Database (MSigDB) hallmark gene sets. Significant gene sets with FDR cutoff of 0.25, n = 4. (m, n) CD8 cell differential gene expression analysis in 20-month-old mice. (m) Volcano plot individual gene FDR cutoff 0.05, n = 4. (n) GSEA significant MSigDB hallmark gene sets with FDR cutoff of 0.25, n = 4.
Figure 4Ndufs2 hemizygosity minimally impacts organismal responses to acute metformin treatment. (a–d) Multiple t-tests, one per time point Ndufs2+ vs NDUFS2+ discovery determined using the Two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 0.05%. Each row was analyzed individually, without assuming a consistent SD. No discoveries. Error bars represent standard error. (a) Glucose tolerance test for females < 6 months of age n = 4–6. (b) Glucose tolerance test females > 20 months of age n = 7–11 per group (c) Glucose tolerance test for males < 6 months of age n = 2–3 per group. (d) Glucose tolerance tests for males > 20 months of age n = 5–7. (e) Oral glucose tolerance test (GTT) with or without 30-min pre-treatment with 200 mg/Kg metformin in Ndufs2+/+ and Ndufs2+/− mice. Ordinary one-way ANOVA p = 0.4275, Sidak’s multiple comparisons tests by genotype not significant. n = 4–8. Error bars represent standard error. (f) Liver tissue differential gene expression analysis from untreated Ndufs2+ mice versus Ndufs2+ mice 8 h after treatment with 200 mg/Kg metformin. Volcano plot individual gene FDR cutoff 0.05. n = 3,5. (g) Liver tissue differential gene expression analysis after 8 h of treatment with 200 mg/Kg metformin in Ndufs2+ vs. Ndufs2+/− mice. Volcano plot individual gene FDR cutoff 0.05. n = 5.
Figure 5Proposed qualitative model of the relationship between mitochondrial electron transport chain impairment and survival and function in vertebrates. Created with https://biorender.com.
| Laser | Laser | Filter | Dye | Antigen | Clone | Vendor |
|---|---|---|---|---|---|---|
| Violet | 405 | 450/50 | eFluor450 | CD11b | M1/70 | Biolegend |
| 525/50 | V500 | CD45 | 30-F11 | BD | ||
| Green | 552 | 575/25 | PE | CD115 | AFS98 | BD |
| 780/60 | PECy7 | CD62L | MEL-14 | eBio | ||
| Red | 640 | 670/30 | APC | CD43 | S11 | Biolegend |
| 780/60 | ACPCy7 | Ly6C | HK1.4 | Biolegend | ||
| Far Red | 690 | 730/45 | Alexa 700 | Ly6G | 18A | BD |